Abstract
94 children with chronic myelocytic leukaemia--CML treated in period 1975-1998 were included in the study. Twenty seven of 60 children were treated with hydroxyurea or busulfan with 6 MP. In 33 children aged 1, 5-17 years IFN (Interferon alfa) was applied at the dose of 3 millions units every second day subcutaneously. Our data showed that IFN alfa could be applied as an alternative treatment in children with CML, who have not a donor for allogenic BMT (bone marrow transplantation).
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Agents / therapeutic use*
-
Bone Marrow Transplantation
-
Busulfan / therapeutic use*
-
Child
-
Child, Preschool
-
Combined Modality Therapy
-
Female
-
Follow-Up Studies
-
Humans
-
Hydroxyurea / therapeutic use*
-
Infant
-
Interferon-alpha / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Male
-
Poland
-
Retrospective Studies
-
Survival Rate
-
Treatment Failure
Substances
-
Antineoplastic Agents
-
Interferon-alpha
-
Busulfan
-
Hydroxyurea